Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million,...
Source: prnewswire.com